---
title: Sai Parenteral's IPO in March 2026 - Apply or Skip
url: https://dhan.co/blog/ipo/sai-parenterals-ipo-should-you-apply/
page_type: blog_post
last_updated: 2026-03-24
---

# Sai Parenteral's IPO - Should You Apply?

The Indian primary market in 2026 continues to see pharmaceutical companies opting for IPOs to raise capital to scale up their manufacturing and increase global reach. The latest offering is Sai Parenteral's IPO that will open for subscription on March 24, 2026, and will close on March 27, 2026.

This IPO is a book-built issue of Rs. 408.79 crore, which includes a fresh issue of Rs. 285 crores and offer for sale (OFS) of 3,157,880 equity shares worth Rs. 123.79 crores. It will be traded in a price band between Rs. 372 to Rs. 392 per share with a minimum lot size of 38 shares at a minimum retail investment of Rs. 14,896.

The allotment is expected to be finalised on March 30, 2026. It is expected to be listed on [BSE](https://dhan.co/blog/stock-market/what-is-bse/) and [NSE](https://dhan.co/blog/stock-market/what-is-nse/) on 2nd April 2026. Here, we will explore the fundamentals of this company and its IPO to let investors decide whether or not to apply for this IPO.

## **Sai Parenteral Company details**

Sai Parenteral's Limited was registered as Sai Parenteral's Private Limited in January 2001, in Hyderabad, Telangana. Over the past 20 years, it has grown from a domestic pharmaceutical manufacturer to a diversified formulations company with an international footprint across Australia, New Zealand, the Middle East, Africa, and South East Asia.

The company has two core business verticals, which include Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) services for domestic and international clients. Sai Parenteral holds and operates five manufacturing facilities in India with an aggregate installed capacity of 1,160 million units per annum. Four are in Hyderabad, Telangana, and one is being run by its wholly owned subsidiary, Revat Laboratories, at Ongole in Andhra Pradesh.

Together, these facilities are accredited to various internationally regulated programs, including WHO-GMP, PIC/S (Pharmaceutical Inspection Co-operation Scheme), and TGA-Australia, which allows the company to export to the Australian and New Zealand markets. The company also recently acquired another company in Australia, namely, Noumed Pharmaceuticals Pty Limited, through its Singapore subsidiary, representing its first overseas acquisition.

Financially, the company is consistently growing and becoming more profitable. In FY25, its revenue from operations was Rs 163.1 crore, up by 6% from Rs 153.7 crore in FY24, and its EBITDA was Rs 39.44 crore in FY25, up by 24.18% from Rs 31.70 crore in FY24.

The fresh issue proceeds of Rs 285 crore would be utilised for capacity expansion and upgradation of existing manufacturing facilities (Rs 110.80 crore); setting up of new Research and development centre (Rs 18.02 crore); repaying/prepaying borrowings (Rs 14.30 crore); working capital requirements (Rs 33.00 crore); repaying the bridge loan availed for the acquisition of Noumed Pharmaceuticals (Rs 35.64 crore) and general corporate purposes.

The lead manager for the book running is Arihant Capital Markets Ltd. Registrar is Bigshare Services Pvt. Ltd.

## **Should you invest in this IPO?**

To know whether to apply for [Sai Parenteral's IPO](https://dhan.co/ipo/sai-parenteral's-ipo/), it is necessary for investors to have a thorough evaluation of the pros and cons of the company. Let's understand them in detail.

### **Pros of investing in Sai Parenteral's IPO**

- Diversified product portfolio with an established track record: Sai Parenteral has a diversified product portfolio across various segments. Its revenue is diversified across therapeutic areas and multiple dosage forms like injectables, tablets, and liquid orals. This diversification reduces product concentration risk significantly and provides resilience against demand softness in any one therapeutic category.
- Strategically located and accredited manufacturing facilities: Its five facilities hold internationally recognised quality certifications like WHO-GMP, PIC/S, and TGA-Australia. The TGA accreditation enables Sai Parenteral to supply to Australia and New Zealand. These accreditations are hard and time-consuming to obtain and act as a competitive barrier for smaller manufacturers looking to enter the export market.
- Well-established distribution network in India and overseas: The company's broad domestic client base of government agencies, public and private hospitals, large pharmaceutical distributors, and retail pharmacies gives its revenue stability. On the international front, the acquisition of Noumed Pharmaceuticals has provided Sai Parenteral with an established commercial presence in Australia and New Zealand, thereby accelerating its entry to the regulated markets.
- IPO proceeds fund real growth: Unlike a pure Offer for Sale, where no IPO proceeds reach the company, here, Rs. 285 crore out of the Rs. 408.79 crore issue is fresh capital for capital expansion and new R&D centre, debt reduction, and the financing of the acquisition of Noumed Pharmaceuticals.
- Improving financial trajectory: In recent years, the company has reported improving financials with its PAT growing 72% year on year from 8.42 crore to 14.43 crore in FY25, coupled with a 24% [EBITDA](https://dhan.co/blog/finance/what-is-ebitda/) expansion to 39.44 crore. It demonstrates the operational leverage of the company and its borrowings diluted from 118.79 crore in FY24 to 76.07 crores by September 2025, which indicates the company’s improving balance sheet quality. For a company like this in the pharmaceutical formulations space, these are meaningful indicators of operational maturity.

### **Cons of investing in Sai Parenteral's IPO**

- **Geographic concentration of facilities**: All the manufacturing facilities of the company are currently concentrated within Telangana and Andhra Pradesh states, exposing manufacturing operations to regional, political, or environmental disruptions.
- **Stringent regulatory compliance**: The pharmaceutical and sterile injectables industries have stringent regulatory compliance. Exposure to regulatory inspections on an ongoing basis by global bodies such as the TGA (Australia) and domestic authorities means any failure to comply could result in product recalls or facility shutdowns.
- **Aggressive valuation**: The IPO is being priced at a trailing P/E multiple of over 72x based on its FY25 earnings, and it is seeking a valuation of almost 10.89X its book value. This makes it one of the most aggressively priced issues when compared to listed peers, leaving a limited margin of safety for retail investors.
- **Dependence on third-party suppliers**: The business is heavily dependent on third-party suppliers for important raw materials and active pharmaceutical ingredients (APIs). Supply chain bottlenecks could have a direct impact on production schedules and profit margins.
- **High product concentration risk**: A substantial portion of the company's historical revenue is highly dependent on injectable formulations (received more than 44% of net revenues in FY25). Any interruption in this particular product category would gravely affect their overall financial health.

## **Conclusion**

The Sai Parenteral's IPO provides Indian investors an opportunity to invest in a pharmaceutical formulations company that offers diversification across therapeutic areas, dosage forms, and geographies, and has internationally accredited manufacturing facilities that provide access to regulated export markets.

The improving financial trajectory of the company, with a reduction in borrowings, all point in the right direction. Additionally, the fresh issue component of the IPO further strengthens its IPO prospects.

However, the highly concentrated manufacturing base in Hyderabad, stringent regulatory compliance, early-stage integration of international acquisition, and the current [GMP](https://dhan.co/blog/ipo/ipo-and-the-grey-market-premium/) of Rs. 0 add a layer of risk to this IPO issue, leading to cautious sentiment among investors.

Investors with a long-term view and conviction in India's pharmaceutical CDMO and export growth might find this IPO issue attractive.
